Benitec Biopharma announced positive interim results from its Phase 1b/2a trial of BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD). Both low and high doses of BB-301 showed durable improvements in swallowing function, with 100% of patients responding to treatment. High dose patients demonstrated greater improvements in throat emptying and swallowing capacity at 3 months post-treatment. No serious adverse events were reported, supporting BB-301's potential as a transformative therapy for OPMD-related dysphagia. The company plans to advance to a pivotal study in mid-2027.
Benitec Biopharma's positive interim Phase 1b/2a results for BB-301 provide context for readers. As of Oct 28, 2026 19:11 WIB, among 150 priced Health-sector US stocks tradable on Pluang, 42 rose and 97 fell. Notable movers include Boston Scientific Corporation (BSX) at USD 39.07 with a 13.29% decline and 99% sell order activity, GE HealthCare Technologies Inc. (GEHC) at USD 77.00 with an 8.28% gain, and BioNano Genomics Inc (BNGO) at USD 1.12 with an 8.20% drop. The most notable figure is the 99% sell order activity for BSX.
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
The Legacy Lab by Team One released its 2026 Legacy Makers 100 list, identifying brands consumers trust to have their best interests at heart and remain relevant long-term. St. Jude Children's Research Hospital topped the list for the second year. Th...
Circuit Mind has introduced AVE (Agentic Verification Engine), an AI-powered application that verifies printed circuit board (PCB) schematics against datasheets and internal design rules to catch errors early and avoid expensive respins. AVE compleme...
Grabar Law Office is investigating claims against officers and directors of Erasca, Planet Fitness, PROCEPT BioRobotics, and The Simply Good Foods Company for alleged breaches of fiduciary duties. The investigations focus on misleading statements and...
